Publication

Towards precision medicine in ANCA-associated vasculitis

van der Geest, K. S. M., Brouwer, E., Sanders, J-S., Sandovici, M., Bos, N. A., Boots, A. M. H., Abdulahad, W. H., Stegeman, C. A., Kallenberg, C. G. M., Heeringa, P. & Rutgers, A., Aug-2018, In : Rheumatology. 57, 8, p. 1332-1339 8 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

van der Geest, K. S. M., Brouwer, E., Sanders, J-S., Sandovici, M., Bos, N. A., Boots, A. M. H., ... Rutgers, A. (2018). Towards precision medicine in ANCA-associated vasculitis. Rheumatology, 57(8), 1332-1339. https://doi.org/10.1093/rheumatology/kex367

Author

van der Geest, Kornelis S M ; Brouwer, Elisabeth ; Sanders, Jan-Stephan ; Sandovici, Maria ; Bos, Nicolaas A ; Boots, Annemieke M H ; Abdulahad, Wayel H ; Stegeman, Coen A ; Kallenberg, Cees G M ; Heeringa, Peter ; Rutgers, Abraham. / Towards precision medicine in ANCA-associated vasculitis. In: Rheumatology. 2018 ; Vol. 57, No. 8. pp. 1332-1339.

Harvard

van der Geest, KSM, Brouwer, E, Sanders, J-S, Sandovici, M, Bos, NA, Boots, AMH, Abdulahad, WH, Stegeman, CA, Kallenberg, CGM, Heeringa, P & Rutgers, A 2018, 'Towards precision medicine in ANCA-associated vasculitis' Rheumatology, vol. 57, no. 8, pp. 1332-1339. https://doi.org/10.1093/rheumatology/kex367

Standard

Towards precision medicine in ANCA-associated vasculitis. / van der Geest, Kornelis S M; Brouwer, Elisabeth; Sanders, Jan-Stephan; Sandovici, Maria; Bos, Nicolaas A; Boots, Annemieke M H; Abdulahad, Wayel H; Stegeman, Coen A; Kallenberg, Cees G M; Heeringa, Peter; Rutgers, Abraham.

In: Rheumatology, Vol. 57, No. 8, 08.2018, p. 1332-1339.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

van der Geest KSM, Brouwer E, Sanders J-S, Sandovici M, Bos NA, Boots AMH et al. Towards precision medicine in ANCA-associated vasculitis. Rheumatology. 2018 Aug;57(8):1332-1339. https://doi.org/10.1093/rheumatology/kex367


BibTeX

@article{cdc741eb3b7f45b6984a0195ff5c7411,
title = "Towards precision medicine in ANCA-associated vasculitis",
abstract = "ANCA-associated vasculitis (AAV) is characterized by inflammation and destruction of small and medium-sized vessels. Current management strategies for AAV have been validated in large groups of patients. However, recent insights indicate that distinct patient subsets may actually exist within AAV, thereby justifying the development of more personalized treatment strategies. In this review, we discuss current evidence for a better classification of AAV based on ANCA type. We describe how thus defined categories of AAV patients may differ in genetic background, clinical presentation, immune pathology, response to treatment and disease outcome. We also explore how these insights may provide a rationale for targeted treatments in different categories of AAV patients. Finally, we provide recommendations on how to further establish precision medicine in AAV.",
keywords = "disease subsets, vasculitis, ANCA, precision medicine, personalized medicine, ANTIBODY-ASSOCIATED VASCULITIS, ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES, NEUTROPHIL EXTRACELLULAR TRAPS, SMALL-VESSEL VASCULITIS, NECROSIS-FACTOR-ALPHA, WEGENERS-GRANULOMATOSIS, T-CELLS, TREATMENT RESISTANCE, RENAL VASCULITIS, EOSINOPHILIC GRANULOMATOSIS",
author = "{van der Geest}, {Kornelis S M} and Elisabeth Brouwer and Jan-Stephan Sanders and Maria Sandovici and Bos, {Nicolaas A} and Boots, {Annemieke M H} and Abdulahad, {Wayel H} and Stegeman, {Coen A} and Kallenberg, {Cees G M} and Peter Heeringa and Abraham Rutgers",
note = "{\circledC} The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.",
year = "2018",
month = "8",
doi = "10.1093/rheumatology/kex367",
language = "English",
volume = "57",
pages = "1332--1339",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "8",

}

RIS

TY - JOUR

T1 - Towards precision medicine in ANCA-associated vasculitis

AU - van der Geest, Kornelis S M

AU - Brouwer, Elisabeth

AU - Sanders, Jan-Stephan

AU - Sandovici, Maria

AU - Bos, Nicolaas A

AU - Boots, Annemieke M H

AU - Abdulahad, Wayel H

AU - Stegeman, Coen A

AU - Kallenberg, Cees G M

AU - Heeringa, Peter

AU - Rutgers, Abraham

N1 - © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

PY - 2018/8

Y1 - 2018/8

N2 - ANCA-associated vasculitis (AAV) is characterized by inflammation and destruction of small and medium-sized vessels. Current management strategies for AAV have been validated in large groups of patients. However, recent insights indicate that distinct patient subsets may actually exist within AAV, thereby justifying the development of more personalized treatment strategies. In this review, we discuss current evidence for a better classification of AAV based on ANCA type. We describe how thus defined categories of AAV patients may differ in genetic background, clinical presentation, immune pathology, response to treatment and disease outcome. We also explore how these insights may provide a rationale for targeted treatments in different categories of AAV patients. Finally, we provide recommendations on how to further establish precision medicine in AAV.

AB - ANCA-associated vasculitis (AAV) is characterized by inflammation and destruction of small and medium-sized vessels. Current management strategies for AAV have been validated in large groups of patients. However, recent insights indicate that distinct patient subsets may actually exist within AAV, thereby justifying the development of more personalized treatment strategies. In this review, we discuss current evidence for a better classification of AAV based on ANCA type. We describe how thus defined categories of AAV patients may differ in genetic background, clinical presentation, immune pathology, response to treatment and disease outcome. We also explore how these insights may provide a rationale for targeted treatments in different categories of AAV patients. Finally, we provide recommendations on how to further establish precision medicine in AAV.

KW - disease subsets

KW - vasculitis

KW - ANCA

KW - precision medicine

KW - personalized medicine

KW - ANTIBODY-ASSOCIATED VASCULITIS

KW - ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES

KW - NEUTROPHIL EXTRACELLULAR TRAPS

KW - SMALL-VESSEL VASCULITIS

KW - NECROSIS-FACTOR-ALPHA

KW - WEGENERS-GRANULOMATOSIS

KW - T-CELLS

KW - TREATMENT RESISTANCE

KW - RENAL VASCULITIS

KW - EOSINOPHILIC GRANULOMATOSIS

U2 - 10.1093/rheumatology/kex367

DO - 10.1093/rheumatology/kex367

M3 - Review article

VL - 57

SP - 1332

EP - 1339

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 8

ER -

ID: 49235396